Midodrine

Basic midodrine information

• INN (international nonproprietary name): Midodrine (as midodrine hydrochloride)
• Brand names available in the United Kingdom: generic midodrine tablets
• ATC code: C01CA17
• Forms and dosages: Oral tablets (typically 2.5 mg and 10 mg)
• Registration status in the United Kingdom: Prescription-only medicine; specialist initiation is usual
• OTC / Rx classification: Prescription-only medicine (POM)

What midodrine is and when it’s used

• Drug class: alpha-1 adrenergic agonist
• Mechanism (one line): increases peripheral vascular resistance to raise standing blood pressure
• Legal status: prescription-only (specialist initiation typical)

Active substance and general class

Midodrine hydrochloride is an oral alpha‑1 adrenergic agonist that works via its active metabolite to constrict peripheral blood vessels.

It is supplied as tablets for oral administration and is a prescription-only medicine in standard practice in the United Kingdom.

Typical patient profiles include those with autonomic failure from Parkinson’s disease, multiple system atrophy or diabetic autonomic neuropathy.

Primary licensed indication

Midodrine’s primary licensed indication is symptomatic orthostatic hypotension where non‑pharmacological measures are inadequate.

The treatment aim is to reduce symptoms such as dizziness, light-headedness and syncope on standing and thereby reduce fall risk.

Off‑label uses commonly seen in practice

Clinicians may occasionally trial midodrine for refractory hypotension in specialist settings or specific peri‑procedural scenarios under specialist oversight.

Off‑label uses are a specialist decision and should involve careful monitoring and documented rationale.

Patients and pharmacists should expect specialist-led initiation for non-standard indications.

Mechanism of action

Pharmacodynamics (practical terms)

Midodrine is a prodrug converted to desglymidodrine, which stimulates alpha‑1 receptors on vascular smooth muscle.

Activation of these receptors produces peripheral vasoconstriction and an increase in standing systolic and diastolic blood pressure.

The practical effect is reduced pooling of blood in the legs on standing and fewer symptoms of orthostatic hypotension.

Onset, duration and clinical relevance

Oral midodrine is absorbed and typically produces a measurable rise in standing blood pressure within 30–60 minutes.

The peak effect is commonly reached around 1–2 hours after a dose and the clinical duration is usually 3–4 hours.

This timing is important for patients to match dosing to periods when they anticipate being upright.

Practical effect on symptoms

Patients often report reduced dizziness and fewer near‑syncope episodes when doses are timed correctly before upright activity.

Avoiding late‑evening doses is important to reduce the risk of supine hypertension while asleep.

Timeline: Dose → Onset 30–60 mins → Peak 1–2 hrs → Duration 3–4 hrs.

Formulations, strengths and packaging

Typical strengths and forms sold

Midodrine is commonly supplied as oral tablets in low and higher strengths to allow titration.

Typical tablet strengths seen in practice include 2.5 mg and 10 mg, though availability varies by supplier.

Pack sizes often include 28 or 56 tablets but can differ between manufacturers.

Brand suppliers and generics

Stock is predominantly generic; suppliers and pack sizes vary.

Packaging and storage

Typical labelling includes drug name, strength, dose instructions, storage advice and manufacturer contact details.

Store midodrine tablets at room temperature, protect from moisture and keep in original packaging to preserve labelling.

Child‑safety blister packs are common; make sure patients know how to read the pack for batch and expiry details.

Dosage, administration and timing

Typical starting regimens

Standard initiation often begins with a low dose such as 2.5 mg taken three times daily.

Clinicians commonly titrate to response, with maintenance doses frequently in the 2.5 mg–10 mg three times daily range.

Maximum doses are defined in specialist guidance and should be confirmed by the prescriber.

Titration and timing for daily activities

Titrate slowly, increasing every 3–7 days while monitoring supine and standing blood pressure.

Arrange doses around planned upright activities; for example, take a dose 30–60 minutes before leaving the house for shopping or appointments.

Do not take a dose within 4 hours of bedtime to reduce the risk of supine hypertension overnight.

Dosing checklist:

• Start low and increase only as advised by prescriber.

• Time doses to cover known upright periods.

• Avoid late evening doses.

1. Titrate: Gradually increase dose to achieve symptom control.

2. Supine hypertension: high BP while lying down; avoid late doses.

3. Orthostatic hypotension: drop in BP on standing that causes symptoms.

Initiation, titration and stopping

Who should initiate midodrine

Initiation is usually performed by a specialist in autonomic disorders, cardiology or neurology, or by an experienced GP following specialist advice.

Pharmacists should verify prescriber details and ensure a documented plan for titration and monitoring is provided.

Monitoring during titration

Ensure recent supine and standing BP readings are available before supply and after dose changes.

Review baseline cardiac history, renal function where relevant, and urinary symptoms.

Recommend review within 1–2 weeks of dose adjustment to check for supine hypertension and symptomatic benefit.

How and when to stop the medicine

Stop therapy if there is no symptomatic benefit after an adequate therapeutic trial (often 2–4 weeks at a therapeutic dose) or if significant adverse effects occur.

Immediate cessation is advised if the patient develops severe supine hypertension, significant urinary retention or serious allergic reaction.

Contraindications and cautions

Absolute contraindications

Do not supply midodrine to patients with uncontrolled supine hypertension.

Avoid use in patients with severe organic heart disease, known hypersensitivity to the drug, pheochromocytoma or urinary retention where it would worsen retention.

Relative cautions

Exercise caution in severe renal impairment — discuss with the prescriber for dose adjustment or specialist review.

Peripheral vascular disease and pregnancy or breastfeeding are relative cautions that need a prescriber discussion.

Older patients require closer supervision due to falls risk and increased likelihood of urinary retention.

Checklist before starting treatment

• Confirm recent supine and standing blood pressure readings.

• Ask about urinary retention symptoms and urinary hesitancy.

• Review cardiovascular history and current medicines that affect blood pressure.

Drug interactions

Major clinically relevant interactions

Midodrine can add to blood pressure effects when used with other vasoconstrictors or sympathomimetics.

MAO inhibitors and some decongestants can potentiate pressor effects and require caution.

Cautions with concurrent antihypertensives and sympathomimetics

When a patient is taking antihypertensive therapy, midodrine may counteract treatment and doses may need review with the prescriber.

A coordinated medication review is essential if the patient uses nitrates, beta‑blockers or high-dose sympathomimetics.

Counselling points for polypharmacy

Advise patients to bring a full medicines list to appointments and to review any drugs that can worsen orthostatic hypotension, such as tricyclic antidepressants, antipsychotics and diuretics.

Ask your prescriber to check interactions if you are on MAOIs, decongestants, strong sympathomimetics or complex antihypertensive regimens.

Side effects, frequency and management

Common adverse effects and their timing

Common effects include piloerection, scalp tingling or paraesthesia and sensations of chills or goosebumps shortly after dosing.

Urinary retention and increased urinary frequency can occur, particularly in patients with underlying outlet obstruction.

Supine hypertension is a major safety concern and may develop after dosing, particularly if doses are taken late in the day.

Red flags requiring urgent review

Advise urgent medical review and immediate cessation if the patient experiences severe chest pain, marked supine hypertension, acute urinary retention or signs of anaphylaxis.

Management tips

• Measure blood pressure both supine and standing and keep a log to show the prescriber.

• Avoid doses within four hours of bedtime to reduce night‑time supine hypertension risk.

• Sit up slowly from lying or seated positions to reduce dizziness and risk of falls.

Monitoring requirements and follow‑up

Baseline checks before dispensing

Baseline supine and standing blood pressure readings are required before initiating midodrine and before significant dose increases.

Consider an ECG if there is a history of cardiac disease and check renal function if clinically indicated.

Document any history of urinary retention or prostatic symptoms in the patient record.

Ongoing monitoring schedule

Check BP within 1–2 weeks of any dose adjustment and then monthly until the dose and response are stable.

When stable, reviews can be spaced to 3–6 monthly intervals depending on clinical circumstances.

Encourage home BP monitoring with supine readings after five minutes rest and standing readings at one and three minutes.

Use in special populations

Elderly considerations and falls risk

Start low and titrate slowly in older patients due to increased sensitivity and higher risk of supine hypertension and urinary retention.

Watch for orthostatic symptoms and assess falls history before supply.

Renal or hepatic impairment

Use with caution in renal impairment and consult the prescriber for dose adjustments if renal function is compromised.

Specialist oversight is recommended for patients with severe chronic kidney disease or significant liver disease.

Pregnancy, breastfeeding and driving

Limited data exist for use in pregnancy and breastfeeding and specialist risk/benefit discussion is advised before use.

Advise patients not to drive until symptomatic control has been achieved and they feel safe; warn about sudden dizziness on standing.

Supply, prescribing and NHS context

Prescription status and MHRA/NHS position

Midodrine is prescription-only and regulated by the MHRA in the United Kingdom.

Specialist initiation is common and regional NHS formularies may have local restrictions or prior approval requirements.

In our online pharmacy, midodrine is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.

Counselling points and FAQ

Key points at first supply

Take the tablet as prescribed, usually three times a day, and do not take any dose within four hours of bedtime.

Measure your blood pressure lying and standing and keep a log for your prescriber.

Stop and seek urgent review if you get severe chest pain, cannot pass urine, or have signs of severe hypertension while lying down.

Frequently asked questions

• What if I feel dizzy after a dose? — Sit or lie down and measure your blood pressure; contact your prescriber if symptoms persist.

• Can I drive? — Only when you feel your symptoms are controlled and you are safe to drive.

• What about other medicines? — Bring a full medicines list; a medication review is recommended if you take antihypertensives or sympathomimetics.

• How quickly will it work? — Often within 30–60 minutes with peak effect at 1–2 hours.

• Do I need to check my BP at home? — Yes; supine and standing readings are useful for monitoring.

• Can I take it at night? — Avoid taking doses within four hours of bedtime to reduce supine hypertension risk.

• What side effects should I expect? — Piloerection, scalp tingling, paraesthesia and possibly urinary symptoms; report severe effects immediately.

• When will my prescriber review my treatment? — Typically within 1–2 weeks of dose changes and periodically thereafter.

When to refer back to prescriber or GP

Seek urgent medical review for chest pain, severe supine hypertension readings, acute urinary retention or a suspected allergic reaction.

Contact the prescriber if symptoms have not improved after an adequate trial or if the patient reports intolerable side effects.

Delivery across the United Kingdom